ArticleFrontiers in cardiovascular medicine2026
Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study.
Mengwei Feng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.